Through subgroup analysis of individuals with or without APOE ε4 status, B2M was found to be significantly associated with CSF AD biomarkers in APOE ε4 carriers but not in non-carriers, suggesting a potential role for B2M in predicting future AD-related risks, particularly in individuals with non-APOE ε4 status. This evidence concerns the gene APOE and Alzheimer disease.